SARA BACHANI: Open Payments
NPI 1407230378 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$597 in 34 payments from 10 companies in 2025. Trend: 2023 $40 · 2024 $259 · 2025 $597
Food & beverage: $589Education: $8
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 13 | $169 |
| E.R. Squibb & Sons, L.L.C. | 7 | $119 |
| Corium, LLC | 4 | $98 |
| Otsuka America Pharmaceutical, Inc. | 3 | $66 |
| Janssen Pharmaceuticals, Inc | 2 | $46 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| ABBVIE INC. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
| HARMONY BIOSCIENCES LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
Products named: Qelbree, COBENFY, Azstarys, REXULTI, SPRAVATO, FANAPT, VRAYLAR, ABILIFY ASIMTUFII.
Industry payments across PA — which companies pay providers there.
